Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 in RSV Seronegative Children

Clicks: 14
ID: 330860
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #471 of 502 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 502 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background An effective RSV vaccine which elicits active immunity and lasting protection could have a significant impact on child health. This study evaluated safety and immunogenicity of three intranasal live-attenuated candidate RSV vaccines, RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 to placebo. Methods Healthy, RSV-seronegative children 6-24 months of age were randomized to receive one of three candidate vaccines or placebo in a blinded manner. Participants were monitored for vaccine reactogenicity and RSV serum antibodies and over the subsequent RSV season. Results Between years 2019 and 2023, 67 participants were randomized, including 20 each to RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and placebo arms and seven to the RSV/276 arm. The RSV/276 arm was closed early due to an excess of mild cough events in another study. The proportion (95% confidence interval) of children who experienced at least one solicited an adverse event during the 28 days after inoculation was 55% (32%, 77%) in the RSV/ΔNS2/Δ1313/I1314L arm, 40% (19%, 64%) in the RSV/6120/ΔNS2/1030s arm, 71% (29%, 96%) in the RSV/276 arm, and 55% (32%, 77%) in the placebo arm. Events were mostly Grade 1 and were often associated with other viruses. The proportion of children with a ≥4-fold increase in serum RSV-neutralizing antibody titer in each of the candidate vaccine arms (>70%) was significantly greater than in the placebo arm (15%). Conclusions RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s had excellent safety and immunogenicity; the assessment of RSV/276 was limited by the small sample size. RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s were deemed suitable for further evaluation.
Reference Key
openalex_W7218563271 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Coleen K. Cunningham, Ruth A. Karron, Elizabeth J. McFarland, Mark J Giganti, Rachel Ketchum, Charlotte Perlowski, Jennifer L. Libous, Haley Brozik, Jennifer Oliva, Dwight Edward Yin, Patrick Jean‐Philippe, Jack Moye, Elizabeth A. Schappell, Emily Barr, Vivian Rexroad, Benjamin Johnston, Grace P. Malonga, Mariam S. Aziz, Tori Rutherford, Heidi Sallee, Jennifer K. Jao, Robert W. Frenck, Jaime Gerardo Deville, Emmanuel B. Walter, James Christopher Day, Stephen A. Spector, Andrés Camacho-González, Joanna Dobroszycki, Sharon Nachman, Mary E. Paul, James Campbell, Xueqiao Liu, Lijuan Yang, Cindy Luongo, Peter L. Collins, Ursula J. Buchholz
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag489
URL
https://doi.org/10.1093/infdis/jiag489
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.